MBRX Latest Press Releases

-- November 4, 2026 --

Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting Globe Newswire 11:00 AM

-- October 30, 2026 --

Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027 Globe Newswire 8:40 AM

-- October 20, 2026 --

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial Globe Newswire 8:12 AM

-- October 16, 2026 --

Moleculin Announces Reverse Stock Split Globe Newswire 9:20 AM

-- October 7, 2026 --

Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit Globe Newswire 8:45 AM

-- September 29, 2026 --

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout Globe Newswire 8:45 AM

-- September 28, 2026 --

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine Globe Newswire 7:00 AM

-- September 25, 2026 --

Annamycin Turns 'Cold' Pancreatic Tumors 'Hot' in New Preclinical Data Presented at AACR Globe Newswire 1:05 PM

-- September 23, 2026 --

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 Globe Newswire 8:25 AM

-- September 14, 2026 --

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings Globe Newswire 8:35 AM

-- September 11, 2026 --

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand Globe Newswire 8:30 AM

-- August 27, 2026 --

JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs ACCESS Newswire 9:01 AM

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor 'Why Now' On-Demand Conference Globe Newswire 9:01 AM

-- August 14, 2026 --

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial Globe Newswire 8:30 AM

-- July 31, 2026 --

Moleculin Announces Pricing of $9.3 Million Public Offering Globe Newswire 10:12 AM

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients Globe Newswire 8:10 AM

-- July 6, 2026 --

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment Globe Newswire 8:33 AM

-- June 30, 2026 --

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control Globe Newswire 8:30 AM

-- June 5, 2026 --

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML Globe Newswire 8:29 AM

Market Data Delayed 15 Minutes